tbuckley/cabot-search huggingface dataset:
The interplay among psychopathology, personal resources, context‐related factors and real‐life functioning in schizophrenia: stability in relationships after 4 years and differences in network structure between recovered and non‐recovered patients
Authors: Silvana Galderisi, Paola Rucci, Armida Mucci, Alessandro Rossi, Paola Rocca, Alessandro Bertolino, Eugenio Aguglia, Mario Amore, Antonello Bellomo, Paola Bozzatello, Paola Bucci, Bernardo Carpiniello, Enrico Collantoni, Alessandro Cuomo, Liliana Dell'Osso, Fabio Di Fabio, Massimo di Giannantonio, Dino Gibertoni, Giulia Maria Giordano, Carlo Marchesi, Palmiero Monteleone, Lucio Oldani, Maurizio Pompili, Rita Roncone, Rodolfo Rossi, Alberto Siracusano, Antonio Vita, Patrizia Zeppegno, Mario Maj
Journal: World Psychiatry (2020)

Improving real‐life functioning is the main goal of the most advanced integrated treatment programs in people with schizophrenia. The Italian Network for Research on Psychoses previously explored, by using network analysis, the interplay among illness‐related variables, personal resources, context‐related factors and real‐life functioning in a large sample of patients with schizophrenia. The same research network has now completed a 4‐year follow‐up of the original sample. In the present study, we used network analysis to test whether the pattern of relationships among all variables investigated at baseline was similar at follow‐up. In addition, we compared the network structure of patients who were classified as recovered at follow‐up versus those who did not recover. Six hundred eighteen subjects recruited at baseline could be assessed in the follow‐up study. The network structure did not change significantly from baseline to follow‐up, and the overall strength of the connections among variables increased slightly, but not significantly. Functional capacity and everyday life skills had a high betweenness and closeness in the network at follow‐up, as they had at baseline, while psychopathological variables remained more peripheral. The network structure and connectivity of non‐recovered patients were similar to those observed in the whole sample, but very different from those in recovered subjects, in which we found few connections only. These data strongly suggest that tightly coupled symptoms/dysfunctions tend to maintain each other's activation, contributing to poor outcome in schizophrenia. Early and integrated treatment plans, targeting variables with high centrality, might prevent the emergence of self‐reinforcing networks of symptoms and dysfunctions in people with schizophrenia.
Safety and Efficacy of Intravenous Cetuximab (CET) and Hepatic Artery Infusion of Irinotecan, 5-Fluorouracil and Oxaliplatin in Patients with Unresectable Liver Metastases from Wt Kras Colorectal Cancer (CRC): Results from Optiliv European Phase II Trial
Authors: F. Levi, V. Boige, P. Rougier, M. Hebbar, D. Smith, C. Focan, R. Guimbaud, C. Carvalho, M. Bouchahda, M. Ducreux
Journal: Annals of Oncology (2012)
Hepatic Arterial Infusion (HAI) of Oxaliplatin Plus Intravenous (IV) Fluorouracil (FU), Leucovorin (LV) and Cetuximab for First-Line Treatment of Unresectable Colorectal Liver Metastases (CRLM): Final Results of a Multicenter Phase 2 Study (CHOICE)
Authors: D. Malka, V. Boige, M. Faron, C. Caramella, E. Boucher, P. Rivera, T. De Baere, D. Goéré, J. Pignon, M. Ducreux
Journal: Annals of Oncology (2012)
Emerging Pharmacological Treatments for Cerebral Edema: Evidence from Clinical Studies
Authors: Jesse A. Stokum, Volodymyr Gerzanich, Kevin N. Sheth, W. Taylor Kimberly, J. Marc Simard
Journal: The Annual Review of Pharmacology and Toxicology (2020)

Cerebral edema, a common and often fatal companion to most forms of acute central nervous system disease, has been recognized since the time of ancient Egypt. Unfortunately, our therapeutic armamentarium remains limited, in part due to historic limitations in our understanding of cerebral edema pathophysiology. Recent advancements have led to a number of clinical trials for novel therapeutics that could fundamentally alter the treatment of cerebral edema. In this review, we discuss these agents, their targets, and the data supporting their use, with a focus on agents that have progressed to clinical trials.
Effect of Post-Protocol Anti-Epidermal Growth Factor Receptor (EGFR) Monoclonal AntiBody (MAB) Therapy on Survival Outcomes in Patients with Wild-Type (WT) Kras Metastatic Colorectal Cancer (MCRC) Treated with Panitumumab (PMAB) Plus Chemotherapy
Authors: J.-Y. Douillard, M. Peeters, A. Rong, S. Siena, S. Braun, R. Sidhu, T. Price
Journal: Annals of Oncology (2012)
Abstract 12227: Patients’ Perceptions of Generic Drugs After Percutaneous Coronary Intervention: A Multicentre Cohort Study
Authors: Trond Røed Pettersen, Jan Schjott, Heather Allore, Bjørn Bendz, Bengt Fridlund, Alf Inge Larsen, Jan Erik Nordrehaug, Svein Rotevatn, Tore Wentzel-Larsen, Tone M Norekvål
Journal: Circulation (2019)

Introduction: Generic drugs are lower-cost bioequivalents to brand-name drugs, and important for reducing healthcare expenditure. However, some patients view generic drugs negatively, believing the...
Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML
Authors: C. D. DiNardo, I. S. Tiong, A. Quaglieri, S. MacRaild, S. Loghavi, F. C. Brown, R. Thijssen, G. Pomilio, A. Ivey, J. M. Salmon, C. Glytsou, S. A. Fleming, Q. Zhang, H. Ma, K. P. Patel, S. M. Kornblau, Z. Xu, C. C. Chua, Xufeng Chen, P. Blombery, C. Flensburg, N. Cummings, I. Aifantis, H. Kantarjian, D. C. S. Huang, A. W. Roberts, I. J. Majewski, M. Konopleva, A. H. Wei
Journal: Blood (2020)
Electric Scooter Injuries and Hospital Admissions in the United States, 2014-2018
Authors: Nikan K. Namiri, Hansen Lui, Thomas Tangney, Isabel E. Allen, Andrew J. Cohen, Benjamin N. Breyer
Journal: JAMA Surgery (2020)

Electric scooters (e-scooters) are a novel, rapid, and convenient mode of transportation with increasing accessibility across the United States. 1 E-scooter use may decrease traffic congestion and increase public transit use. 2 Expansion of e-scooters in dense, high-traffic urban areas will affect rider injury in unknown ways and lead to new policies already implemented by some major cities. 3 With the influx of e-scooter availability in urban areas, particularly in the past year, 3 we sought to investigate trends of injury and hospital admission.
Correction to: “Safety and dose modification for patients receiving niraparib”
Authors: J.S. Berek, U.A. Matulonis, U. Peen, P. Ghatage, S. Mahner, A. Redondo, A. Lesoin, N. Colombo, I. Vergote, O. Rosengarten, J. Ledermann, M. Pineda, S. Ellard, J. Sehouli, A. Gonzalez-Martin, D. Berton-Rigaud, R. Madry, A. Reinthaller, S. Hazard, W. Guo, M.R. Mirza
Journal: Annals of Oncology (2018)
Government orders urgent review of date rape drugs
Authors: Jacqui Wise
Journal: BMJ (2020)

The UK government has asked the Advisory Council on the Misuse of Drugs (ACMD) to urgently review the classification and scheduling of γ-hydroxybutyric acid (GHB), γ-butyrolactone (GBL), and closely related compounds after the sentencing of a prolific rapist.

Reynhard Sinaga is thought to have used GHB to incapacitate young men before raping or sexually assaulting them in his Manchester flat. The mature student, …
18F-FDG-PET/CT Imaging as Survival Predictor in Patients with Metastatic Uveal Melanoma
Authors: A. Rodriguez-Vida, E. Muñoz, M. Ochoa de Olza, S. Rossi, C. Gamez, J.M. Caminal, J. Perez, J. Cortes, J.M. Piulats
Journal: Annals of Oncology (2012)
Interleukin-1β is a potential therapeutic target for periodontitis: a narrative review
Authors: Ran Cheng, Zhiwu Wu, Mingming Li, Meiying Shao, Tao Hu
Journal: International Journal of Oral Science (2020)

Abstract Interleukin(IL)-1β, a pro-inflammatory cytokine, was elevated and participates in periodontitis. Not only the link between IL-1β and periodontitis was proved by clinical evidence, but also the increased IL-1β triggers a series of inflammatory reactions and promotes bone resorption. Currently, IL-1β blockage has been therapeutic strategies for autoimmune and autoinflammatory diseases such as rheumatoid arthritis, cryopyrin-associated periodic syndromes, gout and type II diabetes mellitus. It is speculated that IL-1β be a potential therapeutic target for periodontitis. The review focuses on the production, mechanism, present treatments and future potential strategies for IL-1β in periodontitis.
Abstract 12835: Recurrent Neural Network Enhance Phenotyping in Heart Failure With Preserved Ejection Fraction Using Electronic Health Record
Authors: Hui Ren, Wei Qiu, Aoxiao Zhong, Sijia Yu, Xiang Li, Ning Guo, Quanzheng Li
Journal: Circulation (2019)

Introduction: Current clinical practice guidelines have limited evidence of effective drugs for HFpEF due to its heterogeneous nature. The criteria for phenotype classification remains controversia...
High-Dose Vitamin D Supplementation and Bone Health
Authors: Giuseppe Lippi, Giovanni Targher
Journal: JAMA (2020)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Lurbinectedin as second- or third-line palliative therapy in malignant pleural mesothelioma: an international, multi-centre, single-arm, phase II trial (SAKK 17/16)
Authors: Y. Metaxas, M. Früh, E.I. Eboulet, F. Grosso, M. Pless, P.A. Zucali, G.L. Ceresoli, M. Mark, M. Schneider, A. Maconi, M. Perrino, C. Biaggi-Rudolf, P. Froesch, S. Schmid, C. Waibel, C. Appenzeller, D. Rauch, R. von Moos
Journal: Annals of Oncology (2020)
Efficacy of Cisplatin-Based Chemotherapy as First-Line Treatment in Asian Patients with Metastatic Urothelial Carcinoma Results of an Exploratory Subgroup Analysis of a Pool Analysis of Phase II/III Trials
Authors: C.-C. Lin, M.D. Galsky, S. Krege, N.M. Hahn, T. Ecke, G. Sonpavde, W.K. Oh, A. Bamias
Journal: Annals of Oncology (2012)
Helen Salisbury: When is a consultation not a consultation?
Authors: Helen Salisbury
Journal: BMJ (2020)

“Why has this patient come to see me?” This is a question every doctor asks many times a day. Often the answer is obvious, especially when the patient has a new symptom and wants to know what it signifies and how to make it better. Sometimes the reason is more complicated: perhaps the consultation was prompted by colleagues at work complaining about a persistent cough, or by a partner issuing an ultimatum on doing something about the patient’s weight, mood, or alcohol consumption.

Knowing why the patient has come to your surgery can be a clue as to how seriously your advice is likely to be taken. Many GPs will remember interactions with reluctant but dutiful …
A Phase IB Clinical Trial of the Multitargeted Kinase Inhibitor Lenvatinib (E7080) in Combination with Everolimus for Treatment of Metastatic Renal Cell Carcinoma (RCC)
Authors: A.M. Molina, T.E. Hutson, J. Larkin, A. Gold, C. Andresen, K. Wood, R.J. Motzer, M.D. Michaelson
Journal: Annals of Oncology (2012)
Significant Association Between Vegf-A and ABCB1 Polymorphisms and Survival in Metastatic Pancreatic Adenocarcinoma (MPA) Patients (PTS) Treated with Maintenance Sunitinib (MS)
Authors: M. Reni, E. Giovannetti, S. Cereda, C. Belli, A. Passardi, G. Di Lucca, L. Ferrari, F. Bergamo, A. Novarino, H.M. Verheul
Journal: Annals of Oncology (2012)
P4.02 Proteomics Anchored Systems Biology Analysis of Prognostic Factors in Primary Lung Adenocarcinoma Tumours
Authors: A. Pernemalm, M. Branca, D.E. Petris, J. Forshed, R. Lewensohn, B. Besse, V. Lazar, J. Van den Oord, Y. Pawitan, J. Lehtiö
Journal: Annals of Oncology (2012)
Description of a Subpopulation of Renal Patients with Long-Term Progression Free Survival (PFS) with Sunitinib: A Sog_Gu Experience
Authors: E. Esteban, L. Anton-Aparicio, S. Vazquez-Estevez, U. Anido, F.J. Afonso, O. Fernandez, M. Lazaro, L. Santomé, M. Ramos Vazquez
Journal: Annals of Oncology (2012)
RAGE-induced ILC2 expansion in acute lung injury due to haemorrhagic shock
Authors: Kai Zhang, Yue Jin, Dengming Lai, Jieyan Wang, Yang Wang, Xiaoliang Wu, Melanie Scott, Yuehua Li, Jinchao Hou, Timothy Billiar, Mark Wilson, Qiang Shu, Xiangming Fang, Jie Fan
Journal: Thorax (2020)

Background Type 2 immune dysfunction contributes to acute lung injury and lethality following haemorrhagic shock (HS) and trauma. Group 2 innate lymphoid cells (ILC2s) play a significant role in the regulation of type 2 immune responses. However, the role of ILC2 in post-HS acute lung injury and the underlying mechanism has not yet been elucidated. Objective To investigate the regulatory role of ILC2s in HS-induced acute lung injury and the underlying mechanism in patients and animal model. Methods Circulating markers of type 2 immune responses in patients with HS and healthy controls were characterised. Using a murine model of HS, the role of high-mobility group box 1 (HMGB1)-receptor for advanced glycation end products (RAGE) signalling in regulation of ILC2 proliferation, survival and function was determined. And the role of ILC2 in inducing type 2 immune dysfunction was assessed as well. Results The number of ILC2s was significantly increased in the circulation of patients with HS that was correlated with the increase in the markers of type 2 immune responses in the patients. Animal studies showed that HMGB1 acted via RAGE to induce ILC2 accumulation in the lungs by promoting ILC2 proliferation and decreasing ILC2 death. The expansion of ILC2s resulted in type 2 cytokines secretion and eosinophil infiltration in the lungs, both of which contributed to lung injury after HS. Conclusions These results indicate that HMGB1-RAGE signalling plays a critical role in regulating ILC2 biological function that aggravates type 2 lung inflammation following HS.
Molecular Profile and Anti-Tumor Activity in Non-Small Cell Lung Cancer (NSCLC) Patients (PTS) in a Phase 1 Study of Cabozantinib (XL184) in Japan
Authors: H. Nokihara, N. Yamamoto, S. Nakamichi, H. Wakui, Y. Yamada, J. Frye, A. Decillis, T. Tamura
Journal: Annals of Oncology (2012)
Fulvestrant After Failur of Adjuvant Hormonal Therapy: Multicenter Retrospective Observational Study
Authors: O. Garrone, C. Bighin, F. Vaira, M. Donadio, O. Alabiso, M. Carapezza, E. Baldini, M. Merlano, N. Biglia, P. Pronzato
Journal: Annals of Oncology (2012)
PD-0026 Quality of Life in Patients with Advanced Gastric Cancer Enrolled in the International, Phase 3 Granite-1 Study
Authors: Jaffer Ajani, Jin Li, Taroh Satoh, Tomohiro Nishina, A. Alarcón-Rozas, Junji Furuse, Wei Liu, Min-Hee Ryu, Was Mansoor, Todd Roma, Heind Smith, Jocelynn Booth, Michaela Sedova, Shriya Bhushan, Tarek Sahmoud, Syed Rizvi, Yung-Jue Bang
Journal: Annals of Oncology (2012)
The Novel Cancer Vaccine, Consisting of Genetically Modified Allogeneic Tumor Cells and Immunomodulator MGN1601: Updated Results of a Phase 1-2 Study in Patients with Advanced Renal Cell Carcinoma
Authors: I.G. Schmidt-Wolf, S. Hauser, S. Weikert, V. Grünwald, M. Schroff, M. Schmidt, E. Weith, M. Tschaika, B. Wittig
Journal: Annals of Oncology (2012)
Effects of Benzophenone-3 and Propylparaben on Estrogen Receptor–Dependent R-Loops and DNA Damage in Breast Epithelial Cells and Mice
Authors: Prabin Dhangada Majhi, Aman Sharma, Amy L. Roberts, Elizabeth Daniele, Aliza R. Majewski, Lynn M. Chuong, Amye L. Black, Laura N. Vandenberg, Sallie S. Schneider, Karen A. Dunphy, D. Joseph Jerry
Journal: Environmental Health Perspectives (2020)

Background: Endocrine-disrupting chemicals have been shown to have broad effects on development, but their mutagenic actions that can lead to cancer have been less clearly demonstrated. Physiological levels of estrogen have been shown to stimulate DNA damage in breast epithelial cells through mechanisms mediated by estrogen-receptor alpha (ERα). Benzophenone-3 (BP-3) and propylparaben (PP) are xenoestrogens found in the urine of >96% of U.S. population. Objectives: We investigated the effect of BP-3 and PP on estrogen receptor–dependent transactivation and DNA damage at concentrations relevant to exposures in humans. Methods: In human breast epithelial cells, DNA damage following treatment with 17β-estradiol (E2), BP-3, and PP was determined by immunostaining with antibodies against γ-H2AX and 53BP1. Estrogenic responses were determined using luciferase reporter assays and gene expression. Formation of R-loops was determined with DNA: RNA hybrid–specific S9.6 antibody. Short-term exposure to the chemicals was also studied in ovariectomized mice. Immunostaining of mouse mammary epithelium was performed to quantify R-loops and DNA damage in vivo. Results: Concentrations of 1μM and 5μM BP-3 or PP increased DNA damage similar to that of E2 treatment in a ERα-dependent manner. However, BP-3 and PP had limited transactivation of target genes at 1μM and 5μM concentrations. BP-3 and PP exposure caused R-loop formation in a normal human breast epithelial cell line when ERα was introduced. R-loops and DNA damage were also detected in mammary epithelial cells of mice treated with BP-3 and PP. Conclusions: Acute exposure to xenoestrogens (PP and BP-3) in mice induce DNA damage mediated by formation of ERα-dependent R-loops at concentrations 10-fold lower than those required for transactivation. Exposure to these xenoestrogens may cause deleterious estrogenic responses, such as DNA damage, in susceptible individuals. https://doi.org/10.1289/EHP5221
P-0073 GIDEON (Global Investigation of Therapeutic Decisions in HCC and of its Treatment eith Sorafenib): European Interim Safety and Dosing Subanalysis
Authors: Christos Papandreou, Vlad Ratziu, Vera Gorbunova, Philippe Mathurin, Lluis Castells, György Bodoky, Per Stål, Jean-Pierre Bronowicki, René Gerolami, Bruno Daniele, Juan Turnes Vázquez, Fátima Serejo, Adina Croitoru, Ayala Hubert
Journal: Annals of Oncology (2012)
P-0275 Stereotactic Robotic Radiosurgery for Recurrent Cancer Involving the Gastrointestinal System: Feasability Study
Authors: SridharPapaiah Susheela, B.S. Ajaikumar, M.J. Govindarajan, Monica Gupta, A. Pichandi, Madhu Sudhan
Journal: Annals of Oncology (2012)
Patient-perceived facilitators in the transition of survivorship care from the pediatric to adult care setting.
Authors: Karim Thomas Sadak, Amanda DiNofia, Gregory H. Reaman
Journal: Journal of Clinical Oncology (2012)

9587 Background: Survival rates in childhood cancer continue to rise. A new challenge has emerged in optimizing the transition of pediatric survivorship care to similarly focused programs that are age-appropriate. The purpose of this study is to identify components of a clinical survivorship program that facilitate the transition of care for adult survivors of childhood cancer from the pediatric to adult care-setting. Methods: A descriptive study of childhood cancer survivors was conducted using a cross-sectional study design. A questionnaire was used to identify which clinical components of a survivorship program most influenced the decision to transition care to an adult medical center. Primary data collection occurred through the mail. Secondary mechanisms included an online version of the questionnaire and in-person enrollment during survivorship clinic visits. 140 survivors were eligible but only 129 had valid addresses and received the questionnaire. The study endpoint was achieved when the response rate reached 80% (n=103). A descriptive review of clinical program components was performed using a frequency analysis. Results: Of 129 invited survivors, 103 participated (80%). Mean and median age-range was 20-24 years. There were 49 males (48%) and 54 females (52%). The most common diagnoses were leukemia (40/103), lymphoma (20/103), and CNS tumors (9/103). When asked if the participant was willing to transition their survivorship care to an adult facility, 97 (95%) responded affirmatively. The clinical components most frequently rated “Very Important” in the decision to transition survivorship care were the acceptance of insurance (80/103, 78%) followed by the presence of providers knowledgeable in childhood cancer (68/103, 66%). The clinical components most frequently rated “Very Important” or “Important” were flexible scheduling (102/103, 99%) followed by comprehensive care being offered (101/103, 98%). Conclusions: The decision to transition survivorship care to age-appropriate care-settings is complex and not well understood. Issues related to insurance, clinical team composition, and scheduling appear to be most important for young adult survivors making this decision.
A Treatment-Interaction Analysis Balancing Pathological Complete Responses (PCR) and Cardiotoxicity of Single-(S)/Dual-(D) HER2 Inhibition and Neoadjuvant Chemotherapy (CT) Backbone in Operable/Locally Advanced Breast Cancer (O/LABC) Patients
Authors: E. Bria, M. Bonomi, J. Furlanetto, S. Pilotto, L. Carbognin, F. Massari, E. Lucchini, D. Melisi, D. Giannarelli, G. Tortora
Journal: Annals of Oncology (2012)
Measuring atopic eczema symptoms in clinical practice: The first consensus statement from the Harmonising Outcome Measures for Eczema in clinical practice initiative
Authors: Yael A. Leshem, Joanne R. Chalmers, Christian Apfelbacher, Masutaka Furue, Louise A.A. Gerbens, Cecilia A.C. Prinsen, Jochen Schmitt, Phyllis I. Spuls, Kim S. Thomas, Hywel C. Williams, Eric L. Simpson
Journal: Journal of the American Academy of Dermatology (2020)
Lymphoma Angiogenesis Is Orchestrated by Noncanonical Signaling Pathways
Authors: Marleen Gloger, Lutz Menzel, Michael Grau, Anne-Clemence Vion, Ioannis Anagnostopoulos, Myroslav Zapukhlyak, Kerstin Gerlach, Thomas Kammertöns, Thomas Hehlgans, Maria Zschummel, Georg Lenz, Holger Gerhardt, Uta E. Höpken, Armin Rehm
Journal: Cancer Research (2020)

Abstract Tumor-induced remodeling of the microenvironment relies on the formation of blood vessels, which go beyond the regulation of metabolism, shaping a maladapted survival niche for tumor cells. In high-grade B-cell lymphoma, angiogenesis correlates with poor prognosis, but attempts to target established proangiogenic pathways within the vascular niche have been inefficient. Here, we analyzed Myc-driven B-cell lymphoma–induced angiogenesis in mice. A few lymphoma cells were sufficient to activate the angiogenic switch in lymph nodes. A unique morphology of dense microvessels emerged without obvious tip cell guidance and reliance on blood endothelial cell (BEC) proliferation. The transcriptional response of BECs was inflammation independent. Conventional HIF1α or Notch signaling routes prevalent in solid tumors were not activated. Instead, a nonconventional hypersprouting morphology was orchestrated by lymphoma-provided VEGFC and lymphotoxin (LT). Interference with VEGF receptor-3 and LTβ receptor signaling pathways abrogated lymphoma angiogenesis, thus revealing targets to block lymphomagenesis. Significance: In lymphoma, transcriptomes and morphogenic patterns of the vasculature are distinct from processes in inflammation and solid tumors. Instead, LTβR and VEGFR3 signaling gain leading roles and are targets for lymphomagenesis blockade.